Sequential treatment of afatinib and osimertinib or other regimens in patients with advanced non-small-cell lung cancer harboring EGFR mutations: Results from a real-world study in South Korea.
Taeyun KimTae Won JangChang Min ChoiMi-Hyun KimSung Yong LeeCheol-Kyu ParkYoon Soo ChangKye Young LeeSeung Joon KimSei Hoon YangJeong-Seon RyuJeong Eun LeeShin Yup LeeChan Kwon ParkSang Hoon LeeSeung Hun JangSeong Hoon YoonPublished in: Cancer medicine (2021)
Sequential afatinib and osimertinib treatment resulted in better survival rates than treatment with afatinib followed by other chemotherapies.